Antigenicity of HM10760 in Guinea Pigs |
Choi, Woo-Hyuck
(Korea Institute of Toxicology)
Lee, Sung-Hak (Korea Institute of Toxicology) Lee, Mi-Chael (Korea Institute of Toxicology) Chung, Moon-Ku (Korea Institute of Toxicology) Kwon, Se-Chang (Research Center, Hanmi Pharm Co.) Lee, Gwan-Sun (Research Center, Hanmi Pharm Co.) Han, Jae-Yong (School of Agricultural Biotechnology, Seoul National University) Koh, Woo-Suk (Korea Institute of Toxicology) |
1 | Bitonti, A.J., Dumont, .J.A., Low, S.C., Peters, R.T., Kropp, K.E., Palombella, V.J. Stattel, J.M., Lu, Y, Tan, C.A., Song, J.J., Garcia, A.M., Simister, N.E., Spiekermann, G.M., Lencer, W.I. and Blumberg, R.S. (2004): Pulmonary delivery of an erythropoietin Fc fusion protein in nonhuman primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA, 101, 9763-9768 DOI ScienceOn |
2 | Goldwasser, E., Kung, C.K. and Eliason, J. (1974): On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J. Biol. Chem., 249, 4202-4206 |
3 | Kang, K.K., Cho, H., Baik, N.G. and Kim W.B. (1998): Antigenicity study of recombinant human erythropoietin. J. Appl. Pharmacol., 6, 50-55 과학기술학회마을 |
4 | Osterborg, A. (2004): New erythropoietic proteins: rationale and clinical data. Semin. Oncol., 3, 12-18 DOI PUBMED ScienceOn |
5 | Way, J.C., Lauder, S., Brunkhorst, B., Kong, S.M., Qi, A., Webster, G., Campbell, I., McKenzie, S., Lan, Y., Marelli, B., Nguyen, L.A., Degon, S., Lo, K.M. and Gillies, S.D. (2005): Improvement of Fe-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel., 18, 111-118 DOI ScienceOn |
6 | Glodberg, M.A. and Schneider, T.J. (1994): Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. BioI. Chem., 269, 4355-4359 |
7 | Gershon, S.K., Luksenburg, H., Cote, T.R. and Braun, M.M. (2002): Pure red cell aplasia and recombinant erythropoietin. N. Engl. J. Med., 346,1584-1586 DOI ScienceOn |
8 | Mota, I. and Wong, D. (1969): Homologous and heterologous passive cutaneous anaphylatic activity of mouse antisera during the course of immunization. Life. Sci., 8, 813-820 DOI PUBMED ScienceOn |
9 | Macdougall, I.C. (2005): Antibody-mediated pure cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol. Dial. Transplant., 20, iv9-15 DOI ScienceOn |
10 | Morell, A.G, Irvine, R.A, Sternlieb, I., Scheinberg, I.H. and Ashwell, G (1968): Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J. BioI. Chem., 243, 155-159 |
11 | Saito, T., Urabe, A. and Takaku, F. (1984): in vitro assay of erythropoietin: simple determination in a small amount of human serum samples. Jpn. J. Med., 23, 16-21 DOI |
12 | Karol, M.H. and Graham, C. (1997): Antibody-mediated hypersensitivity. in [Comprehensive toxicology; Ed. Lawrence D.A., vol. 5 (Toxicology of the immune system)], Pergamon Press, New York, pp. 305-322. |
13 | Sytkowski, A.J., Lunn, E.D., Risinger, MA and Davis, K.L. (1999): An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological prop- erties. J. Bioi. Chem., 274, 24773-24778 DOI |
14 | Cooper, J.C., Morgan, G, Harding, S., Subramanyam, M., Majeau, G.R, Moulder, K. and Alexander, D.R. (2003): Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J. Immunol., 33, 666-675 DOI ScienceOn |
15 | Eschbach, J.W, Egrie, J.C., Downing, M.R., Browne, J.K and Adamson, J.W. (1987): Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med., 316, 73-78 DOI ScienceOn |
16 | Wallner, S.F., Kurnick, J.E., Vautrin, R.M., White, M.J., Chapman, R.G. and Ward, H.P. (1977): Levels of erythropoietin in patients with the anemias of chronic diseases and liver failure. Am. J. Hematol., 3, 37-44 DOI |
![]() |